RedHill Biopharma (RDHL) Enterprise Value (2013 - 2025)

RedHill Biopharma (RDHL) has reported Enterprise Value for 13 consecutive years, with $8.6 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Enterprise Value fell 99.46% year-over-year to $8.6 million in Q4 2025; TTM through Dec 2025 was $8.6 million, a 99.46% decrease from a year earlier, with the FY2025 full-year figure at $8.6 million, down 99.46% from the prior year.
• Enterprise Value was $8.6 million for Q4 2025 at RedHill Biopharma, down from $488.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at $281.0 billion in Q1 2021 and troughed at $8.6 million in Q4 2025.
• A 5-year average of $72.8 billion and a median of $9.5 billion in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 75.97% in 2021 and sank 99.46% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at $135.9 billion in 2021, then sank by 93.63% to $8.7 billion in 2022, then rose by 9.27% to $9.5 billion in 2023, then sank by 83.04% to $1.6 billion in 2024, then slumped by 99.46% to $8.6 million in 2025.
• The last three Enterprise Value figures came in at $8.6 million (Q4 2025), $488.8 million (Q2 2025), and $1.6 billion (Q4 2024), per Business Quant data.